Study to Evaluate the Efficacy and Tolerability of Venaflon Use in Reducing the Symptoms Caused by Chronic Venous Insufficiency When Compared With Daflon

• Patients of any ethnic group, both sexes and aged at least 18 years and a maximum of 65 years
• Women and men of childbearing age who agree to use acceptable contraception throughout the study.
• Be patient with chronic venous insufficiency of lower limbs varicose comDiagnostico clinical CEAP 0-3 by CEAP
• Presence of at least 23 symptoms (pain, heaviness and discomfort, symptoms of heat and burning sensation in the legs) in the lower limbs, with a score equal to or greater than 4, as measured by visual analog scale
• Being the 7 days without any medication or treatment related to the venous system.
• Patients able to make proper use of medication
• Patients who consent to participate in the study by signing the Instrument of Consent.

Exclusion Criteria:

• Pregnant or breastfeeding women
• Women who are breastfeeding
• Women and men of childbearing age who do not accept to use acceptable contraception throughout the study
• Patients under 18 or over 65 years
• Patients with a history of hypersensitivity to any component of the formula
• Presence of signs and symptoms of different conditions of venous disease to justify the pain or swelling
• Use of elastic compression in the last two weeks
• Venous obstruction of the lower limbs
• Patients who have previously used or Venaflon Daflon and did not benefit;
• Deep vein thrombosis in the last 6 months before entering the study;
• Use of diuretics in the last 4 weeks
• Previous venous surgery
• Patients with renal and liver failure
• Patients with gastritis or gastric ulcer
• Patients with blood clotting disorders
• Any condition which in the opinion of the physician researcher is significant and can make the patient unsuitable for study or you can place it under additional risk